Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

BioCorRx (BICX) Accounts Payables (2016 - 2025)

BioCorRx (BICX) has disclosed Accounts Payables for 16 consecutive years, with $6.4 million as the latest value for Q4 2025.

  • Quarterly Accounts Payables rose 14.13% to $6.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $6.4 million through Dec 2025, up 14.13% year-over-year, with the annual reading at $6.4 million for FY2025, 14.13% up from the prior year.
  • Accounts Payables hit $6.4 million in Q4 2025 for BioCorRx, up from $2828.0 in the prior quarter.
  • In the past five years, Accounts Payables ranged from a high of $11.8 million in Q2 2025 to a low of $2828.0 in Q3 2025.
  • Historically, Accounts Payables has averaged $4.7 million across 5 years, with a median of $4.2 million in 2023.
  • Biggest YoY gain for Accounts Payables was 121.49% in 2025; the steepest drop was 99.95% in 2025.
  • Year by year, Accounts Payables stood at $3.2 million in 2021, then grew by 22.56% to $3.9 million in 2022, then increased by 18.97% to $4.6 million in 2023, then increased by 19.91% to $5.6 million in 2024, then increased by 14.13% to $6.4 million in 2025.
  • Business Quant data shows Accounts Payables for BICX at $6.4 million in Q4 2025, $2828.0 in Q3 2025, and $11.8 million in Q2 2025.